Progressive Corp vs Relay Therapeutics Inc. Common Stock — how do they compare? Progressive Corp trades at $217.5 (market cap $126.95B), while Relay Therapeutics Inc. Common Stock trades at $18.03 (market cap $3.82B). The key difference: Progressive Corp is far larger — about 33.2× Relay Therapeutics Inc. Common Stock's market cap, and Progressive Corp pays a 0.18% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| PGR | RLAY | |
|---|---|---|
Market Cap | $126.95B | $3.82B |
Volume | 2,749,438 | 4,332,079 |
Sector | Financials | Health |
52-Week High | $242.16 | $20.75 |
52-Week Low | $190.40 | $6.03 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $135.16B | $2.93B |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $217.43, up 1.55% with a bullish technical outlook supported by moving averages and strong institutional interest. The company demonstrates robust fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025, net income reaching $11.3B, and impressive profitability metrics including 34.94% ROE. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 2026 missed, with Q3 2026 results pending.
The stock presents a compelling value opportunity with a P/E of 10.97 and positive analyst sentiment (38.1% buy ratings), though competitive pressures in auto insurance and potential market volatility pose risks. With a consensus price target of $222.23 offering modest upside, PGR remains well-positioned for long-term growth given its operational strength and dividend consistency.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →